Back to Search
Start Over
Outcomes of myeloablative peripheral blood stem cell transplantation for non-complete remission patients with relapsed/refractory peripheral T cell lymphomas.
- Source :
-
Annals of Hematology . May2019, Vol. 98 Issue 5, p1237-1247. 11p. - Publication Year :
- 2019
-
Abstract
- There was limited information about the efficacy of myeloablative allogeneic peripheral blood stem cell transplantation (allo-PBSCT) in non-complete remission (non-CR) patients with relapsed/refractory peripheral T cell lymphomas (PTCLs). We conducted a retrospective study of 21 consecutive non-CR patients with relapsed/refractory PTCLs who received myeloablative allo-PBSCT between January 2008 and June 2016. The median follow-up of survivors was 46.5 months (range, 14-105 months). The estimated 3-year relapse rate was 24% (95% CI, 9 to 43%). The 3-year non-relapsed mortality rate was 24% (95% CI, 9 to 44%). Overall, the estimated 3-year overall survival was 47% (95% CI, 25 to 66%). And the estimated 3-year progression-free survival was 46% (95% CI, 24 to 66%). Specifically, eight patients failed to achieve a CR at the first evaluation 3 months after allo-PBSCT and received withdraw of immunosuppression. Five patients also received donor lymphocytes infusions. Five (5/8, 62.5%) patients responded subsequently to these interventions (complete = 4, partial = 1). Overall, ten patients were alive at our last follow-ups, and durable CR were achieved in nine patients without further therapy. Five (50%) of these ten alive patients experienced chronic graft-versus-host disease (GVHD). Our favorable clinical outcomes suggested myeloablative allo-PBSCT was a valid therapeutic option for non-CR patients with relapsed/refractory PTCLs. The sustained CR after immunotherapeutic intervention and high prevalence of chronic GVHD in alive patients provided evidence of graft versus T cell lymphoma effects. [ABSTRACT FROM AUTHOR]
- Subjects :
- *STEM cell transplantation
*T cells
*BLOOD cells
*GRAFT versus host disease
*PROGRESSION-free survival
*CHRONIC diseases
*CLINICAL trials
*COMPARATIVE studies
*HEMATOPOIETIC stem cell transplantation
*IMMUNOSUPPRESSION
*LONGITUDINAL method
*RESEARCH methodology
*MEDICAL cooperation
*PROGNOSIS
*RESEARCH
*EVALUATION research
*DISEASE prevalence
*RETROSPECTIVE studies
*T-cell lymphoma
*THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 09395555
- Volume :
- 98
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Annals of Hematology
- Publication Type :
- Academic Journal
- Accession number :
- 135891188
- Full Text :
- https://doi.org/10.1007/s00277-018-3559-3